Eli Lilly buys a Roche discard in $1.1B Dermira buyout. Can they go toe-to-toe with the heavyweight challenger Dupixent?
Eli Lilly thinks it has found a better way to tackle the atopic dermatitis market now being dominated by Dupixent.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.